Find local coverage information for your patients
Demonstrated strength of KERENDIA payer coverage6
of Medicare patients
of commercially insured patients
of fee-for-service Medicaid patients
Access a full suite of resources available for your practice to help get your patients access to KERENDIA:
Learn about the PA Process:
Prior Authorization Checklist
Review these additional resources to help guide you through patient access to KERENDIA:
Sample Letter of Medical Necessity
*CoverMyMeds® is an independent party.
KERENDIA is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D)
Hyperkalemia: KERENDIA can cause hyperkalemia. The risk for developing hyperkalemia increases with decreasing kidney function and is greater in patients with higher baseline potassium levels or other risk factors for hyperkalemia. Measure serum potassium and eGFR in all patients before initiation of treatment with KERENDIA and dose accordingly. Do not initiate KERENDIA if serum potassium is >5.0 mEq/L
Measure serum potassium periodically during treatment with KERENDIA and adjust dose accordingly. More frequent monitoring may be necessary for patients at risk for hyperkalemia, including those on concomitant medications that impair potassium excretion or increase serum potassium
Please read the Prescribing Information for KERENDIA.